Selpercatinib and pralsetinib are selective <i>RET</i> inhibitors with significant improvement of outcome in patients with tumor harboring <i>RET</i> fusion; however, resistance mechanisms appear frequently, mainly driven by MAPK pathway bypass, secondary <i>RET</i> mutations, or in 5% via <i>MET</i> amplification. Here, MET is linked to neoplasm.